{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo-P&page=2",
    "query": {
      "intervention": "placebo-P",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo-P&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T03:37:37.837Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00656110",
      "title": "Neuroma Injections to Treat Restless Legs Syndrome - RCT",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Restless Legs Syndrome"
      ],
      "interventions": [
        {
          "name": "equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml",
          "type": "DRUG"
        },
        {
          "name": "Normal saline - 1ml",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lowcountry Infectious Diseases",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2008-04",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2009-03-10",
      "last_synced_at": "2026-09-28T03:37:37.837Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00656110"
    },
    {
      "nct_id": "NCT03496467",
      "title": "Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pain",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Nepafenac PPDS",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo PPDS",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Mati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "22 Years to 99 Years"
      },
      "enrollment_count": 56,
      "start_date": "2018-03-05",
      "completion_date": "2018-12-17",
      "has_results": true,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-09-28T03:37:37.837Z",
      "location_count": 3,
      "location_summary": "Edgewood, Kentucky • Garden City, New York • Mt. Pleasant, South Carolina",
      "locations": [
        {
          "city": "Edgewood",
          "state": "Kentucky"
        },
        {
          "city": "Garden City",
          "state": "New York"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03496467"
    },
    {
      "nct_id": "NCT07709494",
      "title": "A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants",
        "Non-cystic Fibrosis Bronchiectasis"
      ],
      "interventions": [
        {
          "name": "Rev-56 for Inhalation",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo: Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Revagenix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 64,
      "start_date": "2026-07-13",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-09-28T03:37:37.837Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07709494"
    },
    {
      "nct_id": "NCT03669614",
      "title": "SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Inhaled AR-501",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aridis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 102,
      "start_date": "2018-12-07",
      "completion_date": "2023-07",
      "has_results": false,
      "last_update_posted_date": "2023-03-09",
      "last_synced_at": "2026-09-28T03:37:37.837Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • Long Beach, California • Denver, Colorado + 22 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03669614"
    },
    {
      "nct_id": "NCT05065372",
      "title": "MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes",
        "Diabetic Kidney Disease",
        "Cardiovascular Diseases",
        "Endothelial Dysfunction",
        "Insulin Sensitivity"
      ],
      "interventions": [
        {
          "name": "Metformin Hcl 1000Mg Tab",
          "type": "DRUG"
        },
        {
          "name": "Aminohippurate Sodium 20 % Injection",
          "type": "DRUG"
        },
        {
          "name": "Iohexol 300 Mg/mL Injectable Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kalie Tommerdahl",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "12 Years to 25 Years"
      },
      "enrollment_count": 60,
      "start_date": "2022-07-01",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-09-28T03:37:37.837Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Seattle, Washington",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05065372"
    },
    {
      "nct_id": "NCT00383786",
      "title": "Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PTSD"
      ],
      "interventions": [
        {
          "name": "NK1 Antagoist (GR205171)",
          "type": "DRUG"
        },
        {
          "name": "Psychophysiology (Trauma Script)",
          "type": "PROCEDURE"
        },
        {
          "name": "Psychophysiology (Verbal Threat)",
          "type": "PROCEDURE"
        },
        {
          "name": "Psychophysiology (Fear Conditioning)",
          "type": "PROCEDURE"
        },
        {
          "name": "Psychophysiology (Affective Modulation)",
          "type": "PROCEDURE"
        },
        {
          "name": "Psychophysiology (Heart rate variability)",
          "type": "PROCEDURE"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "24-hour plasma sampling",
          "type": "PROCEDURE"
        },
        {
          "name": "MRI",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 47,
      "start_date": "2006-09",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2019-07-31",
      "last_synced_at": "2026-09-28T03:37:37.837Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • New York, New York",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00383786"
    },
    {
      "nct_id": "NCT01245634",
      "title": "A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Heart Disease, Graft Occlusion, Vascular"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "RO4905417",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 384,
      "start_date": "2010-12",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-09-28T03:37:37.837Z",
      "location_count": 27,
      "location_summary": "Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 21 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01245634"
    },
    {
      "nct_id": "NCT00689611",
      "title": "Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Coronary Syndrome",
        "Myocardial Infarction",
        "Smoking"
      ],
      "interventions": [
        {
          "name": "Bupropion HCl ER",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mark Eisenberg",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 392,
      "start_date": "2005-12",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2015-04-23",
      "last_synced_at": "2026-09-28T03:37:37.837Z",
      "location_count": 13,
      "location_summary": "Pueblo, Colorado • Lewiston, Maine • Bay City, Michigan + 9 more",
      "locations": [
        {
          "city": "Pueblo",
          "state": "Colorado"
        },
        {
          "city": "Lewiston",
          "state": "Maine"
        },
        {
          "city": "Bay City",
          "state": "Michigan"
        },
        {
          "city": "Cooperstown",
          "state": "New York"
        },
        {
          "city": "Johnson City",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00689611"
    },
    {
      "nct_id": "NCT02544750",
      "title": "An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tuberous Sclerosis Complex",
        "Seizures"
      ],
      "interventions": [
        {
          "name": "GWP42003-P",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "1 Year to 65 Years"
      },
      "enrollment_count": 199,
      "start_date": "2016-08-31",
      "completion_date": "2021-06-11",
      "has_results": true,
      "last_update_posted_date": "2022-07-14",
      "last_synced_at": "2026-09-28T03:37:37.837Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02544750"
    },
    {
      "nct_id": "NCT04072302",
      "title": "Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "KAF156",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "MALE",
        "summary": "18 Years to 40 Years · Male only"
      },
      "enrollment_count": 86,
      "start_date": "2014-09-15",
      "completion_date": "2017-11-29",
      "has_results": false,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-09-28T03:37:37.837Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04072302"
    }
  ]
}